LONG®R3 IGF-I is a critically important mitogenic growth factor often used in mammalian cell culture to increase yield significantly. Such growth factors are fundamental supplements to chemically-defined media. LONG®R3 IGF-I is a recombinant analog of human insulin-like growth factor-I (IGF-I) that has been specifically engineered for the enhancement of cell culture performance.
LONG®R3 IGF-I is compatible with multiple cell types. Any mammalian cell type that responds to insulin in cell culture has the potential to respond to LONG®R3 IGF-I.
200 times more potent and 2 times more stable in cell culture than insulin
Enables more streamlined cell culture feeding strategies with increased cell density, higher viability and extended culture duration
Dry or liquid format, use with multiple cell types
Helps ensure regulatory acceptance through an animal-free manufacturing process
Mitigates risk through inventory backed by comprehensive supply chain risk management
Reduces cold chain shipping and storage costs since LONG®R3 IGF-I ships at ambient conditions and stored at 2-8°C
Repligen develops and manufactures products for the biopharmaceutical industry under an ISO 9001 quality management system. We focus on the timely delivery of high quality, consistent and robust products, to ensure business continuity for our customers.
LONG®R3 IGF-I is compatible with multiple cell types. Any mammalian cell type that responds to insulin in cell culture has the potential to respond to LONG®R3 IGF-I.
LONG®R3 IGF-I is available in two formats, both stable at 2-8°C. LONG®R3 IGF-I can also be milled into cell culture media for additional flexibility and convenience.
Freeze-dried powder
Ready to use liquid
*Sample size is not fully validated. The material is filled from validated intermediate material. Stability information is inferred from the stability trials for 100mL and 50mg respectively.
Cell culture supplements are essential for long-term growth and productivity of cell lines in serum-free media formulations. Both insulin and LONG®R3 IGF-I, a more potent supplement that directly targets and activates the IGF-I receptor, are employed by the biopharmaceutical industry today to support the growth of recombinant cell lines. This webinar will show how these two supplements, used separately and in combination, impact viable cell density and IgG production of multiple CHO cell lines. It will demonstrate how a combination of LONG®R3 IGF-I and insulin results in less protein supplementation and, therefore, less potential impact on downstream processing.
LONG® technology consists of a fusion of the growth factor with a portion of growth hormone sequence. The fusion improves growth factor production without imparting its biological activity.
A distinct biological advantage
All mammalian cells secrete IGF Binding Proteins (IGFBPs) which bind to and inhibit native IGF-I. The substitution of an arginine for glutamic acid at position three in LONG®R3 IGF-I, in conjunction with the 13 amino acid N-terminal extension peptide, results in > 1000 fold reduced affinity for IGFBPs, enhancing its bio-availability and effectiveness in comparison to native IGF-I.
Specificity is the key to increased productivity
Unlike insulin, LONG®R3 IGF-I specifically targets and activates the type I IGF Receptor (IGF-IR) resulting in greater activation of downstream signaling cascades responsible for proliferation and inhibiting apoptosis. Greater activation of these key pathways results in increased cell density, higher viability and extended cell culture productivity.
To learn more about the use of LONG®R3 IGF-I in stem cell and cell therapy applications, please contact Repligen.
LONG®R3 IGF-I has been shown to improve volumetric productivity in CHO cell culture by up to 62% over cell culture with no supplementation and 40% over cell culture supplemented with insulin.
LONG®R3 IGF-I is backed by one of the most comprehensive risk mitigation strategies for any cell culture raw material. Repligen manages a global inventory safety stock of over 2 years forecasted demand. This inventory, together with multi-site manufacturing capability, ensures an uninterrupted supply to customers.
Repligen develops and manufactures products for the biopharmaceutical industry under an ISO 9001 quality management system. We focus on the timely delivery of high quality, consistent and robust products, and ensuring business continuity for our customers.
The LONG®R3 IGF-I ELISA Kit is the only commercially available kit for the quantitation of LONG®R3 IGF-I. Fast, accurate, and easy to use with both cell culture and drug substance samples, this sandwich ELISA kit uses a biotinylated secondary antibody and Streptavidin-HRP for detection
Kit Contents:
LONG®R3 IGF-I is not approved or permitted for use in any human application. Repligen provides LONG®R3 IGF-I only to qualified customers expressly for use in cell culture supplementation or for other research purposes.